Diabetes research and clinical practice最新文献

{"title":"Association of reticulocyte-related indices with metabolic syndrome and its components: Evidence from the China National Health Survey","authors":"Lunhui Huang ,&nbsp;Binbin Lin ,&nbsp;Guoqing Zhu ,&nbsp;Yueyi Mu ,&nbsp;Yansong Ren ,&nbsp;Qiang Li ,&nbsp;Yong Li ,&nbsp;Yueshen Ma ,&nbsp;Yulong Fan ,&nbsp;Xuehang Li ,&nbsp;Miao Yu ,&nbsp;Yuqing Wang ,&nbsp;Chunyan Ping ,&nbsp;Huijing He ,&nbsp;Yaoda Hu ,&nbsp;Zhen Song ,&nbsp;Yonghui Xia","doi":"10.1016/j.diabres.2025.112917","DOIUrl":"10.1016/j.diabres.2025.112917","url":null,"abstract":"<div><h3>Background</h3><div>Reticulocyte-related indices have emerged as promising biomarkers for various hematologic and metabolic disorders. However, their associations with metabolic syndrome (MetS) and the underlying mechanisms remain poorly understood. This study aimed to examine the relationship between reticulocyte-related indices and MetS, evaluate their predictive utility, and explore the potential mediating role of inflammation.</div></div><div><h3>Methods</h3><div>This cross-sectional study included 6,098 Chinese adults aged 18 years and older. Reticulocyte-related indices, such as reticulocyte count (RET#), reticulocyte percentage (RET%), low/medium/high fluorescence reticulocytes (LFR, MFR, HFR), reticulocyte hemoglobin equivalent (RET-HE), immature reticulocyte fraction (IRF), and reticulocyte production indices (RPI), were analyzed for their associations with MetS. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable logistic regression. Stratified analyses assessed potential interactions, while restricted cubic spline (RCS) regression evaluated nonlinear dose–response relationships. Mediation analysis explored the role of inflammatory markers in linking reticulocyte-related indices to MetS.</div></div><div><h3>Results</h3><div>After multivariable adjustment, participants in the highest quartile of reticulocyte-related indices, excluding LFR and RET-HE, exhibited at least a two-fold increased risk of MetS. The ORs (95% CIs) for the highest vs. lowest quartile were as follows: RET# 5.45 (4.56, 6.51), RET% 4.09 (3.44, 4.85), IRF 2.97 (2.51, 3.52), MFR 2.23 (1.89, 2.63), HFR 3.54 (2.99, 4.21), and RPI 4.19 (3.53, 4.98). Conversely, LFR showed a protective association (highest vs. lowest quartile OR: 0.33, 95% CI: 0.28, 0.40). RET-HE was significantly associated with low high-density lipoprotein cholesterol and high waist circumference. Subgroup analyses revealed stronger associations among younger individuals, males, and those without obesity. RCS regression indicated nonlinear relationships between various reticulocyte-related indices and MetS. Inflammation was found to partially mediate the associations between reticulocyte-related indices and MetS.</div></div><div><h3>Conclusion</h3><div>This study identifies reticulocyte indices, particularly RET#, RET%, and IRF, as strongly associated with MetS, highlighting their potential utility in early screening and personalized risk stratification. These findings provide new insights into the role of erythropoiesis in metabolic health. Further longitudinal research is needed to elucidate the underlying mechanisms and validate the clinical applications of reticulocyte indices in managing MetS.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112917"},"PeriodicalIF":7.4,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-related differences of diabetic cardiomyopathy.","authors":"Olivia Zeiler Ell, Annemie S Bojer, Martin H Sørensen, Peter Gæde, Per Lav Madsen","doi":"10.1016/j.diabres.2025.112920","DOIUrl":"https://doi.org/10.1016/j.diabres.2025.112920","url":null,"abstract":"<p><strong>Aims: </strong>It is well known that patients with type 2 diabetes (T2D) have an increased risk of both ischemic and non-ischemic heart disease. We studied sex differences in the microvascular function and myocardial extracellular fibrosis that underlie cardiac dysfunction METHODS: In a cross-sectional echocardiography and cardiovascular magnetic resonance imaging study, myocardial extracellular volume fraction (ECV), myocardial blood flow at rest (MBF_rest) and during adenosine-induced stress (MBF_stress), and the myocardial perfusion reserve (MPR) were determined in 221 patients with T2D without ischemic heart disease and 25 age-matched controls. We investigated sex-related differences in MBF, MPR, ECV, and diastolic and systolic function.</p><p><strong>Results: </strong>Both in unadjusted analyses and after multiple linear regression analyses adjusted for known confounders, women with T2D had higher MBF_rest, MBF_stress, and ECV than men. The differences in microvascular function resulted in T2D men and women both having lower MPR compared to healthy controls, but the underlying causes differed. Female sex associated with lower lateral e' and higher E/e' independently of MBF_stress and ECV.</p><p><strong>Conclusions: </strong>These findings highlight distinct sex-specific mechanisms of microvascular dysfunction and myocardial remodeling in T2D. Recognizing these differences may be critical for improving risk stratification and guiding targeted preventive strategies in diabetic cardiomyopathy.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"112920"},"PeriodicalIF":7.4,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End-stage renal diseases associated with SGLT2 inhibitors versus GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease","authors":"Hwa Yeon Ko ,&nbsp;Bin Hong ,&nbsp;Sungho Bea ,&nbsp;Jae Hyun Bae ,&nbsp;Young Min Cho ,&nbsp;Yoosoo Chang ,&nbsp;Seungho Ryu ,&nbsp;Christopher D Byrne ,&nbsp;Ju-Young Shin","doi":"10.1016/j.diabres.2025.112921","DOIUrl":"10.1016/j.diabres.2025.112921","url":null,"abstract":"<div><h3>Aims</h3><div>To compare the renal effectiveness of SGLT2 inhibitors (SGLT2i) versus GLP-1 receptor agonists (GLP-1RA) in metabolic dysfunction-associated steatotic liver disease (MASLD).</div></div><div><h3>Methods</h3><div>Using nationwide healthcare claims (2014–2023) of Korea, we constructed a cohort of MASLD patients who initiated SGLT2i or GLP-1RA. Patients were stratified on baseline status of chronic kidney disease (CKD). New-users of SGLT2i and GLP-1RA were 1:1 propensity score (PS) matched. Incidence rates (IRs) per 1,000 person-years, hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for a composite of end-stage renal diseases (ESRD).</div></div><div><h3>Results</h3><div>Of 333,082 MASLD patients who initiated SGLT2i or GLP-1RA, a total of 1,268 SGLT2i-GLP-1RA pairs were PS-matched in cohort with CKD, while 10,996 pairs were matched in cohort without CKD. For the cohort with CKD, SGLT2i presented 33% lower risk of ESRD compared to GLP-1RA (20.3 vs. 30.0 events per 1,000 person-years; HR 0.67, 95% CI 0.45–1.00). For the cohort without CKD, SGLT2i presented a 68% lowered risk of ESRD compared to GLP-1RA (0.9 vs. 2.5 events per 1,000 person-years; HR 0.32, 95% CI 0.19–0.53).</div></div><div><h3>Conclusions</h3><div>The use of SGLT2i was associated with lower risk of ESRD compared to GLP-1RA in MASLD. The protective association was presented regardless of CKD status.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112921"},"PeriodicalIF":7.4,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do circadian factors improve mortality risk prediction? A dual-cohort analysis of metabolic and circadian syndromes","authors":"Da Pan ,&nbsp;Yuanyuan Wang ,&nbsp;Chen Zhang ,&nbsp;Yifei Lu ,&nbsp;Shiyu Yin ,&nbsp;Pei Wang ,&nbsp;Jiayue Xia ,&nbsp;Junhui Yu ,&nbsp;Han Gao ,&nbsp;Guiju Sun ,&nbsp;Dengfeng Xu","doi":"10.1016/j.diabres.2025.112919","DOIUrl":"10.1016/j.diabres.2025.112919","url":null,"abstract":"<div><h3>Aims</h3><div>This study prospectively evaluated the associations between metabolic syndrome (MetS), circadian syndrome (CircS) and mortality from major diseases.</div></div><div><h3>Methods</h3><div>We conducted prospective analyses using data from two large cohorts: NHANES (n = 14,727 for MetS; 13,799 for CircS, aged ≥ 20 years) and the UK Biobank (n = 404,028 for MetS; 376,236 for CircS, aged ≥ 40 years). We assessed associations between MetS, CircS, and all-cause, cardiovascular, and cancer mortality, using Cox proportional hazards models. Model performance was compared using C-index, Brier Score, AIC, and BIC.</div></div><div><h3>Results</h3><div>In NHANES, the prevalences of MetS and CircS were 41.1 % and 31.7 %, respectively, while in UKB, they were 29.9 % and 17.6 %, respectively. In fully adjusted models, MetS was significantly associated with a 21 % increase in all-cause mortality, and CircS was significantly associated with a 34 % increase in all-cause mortality and a 65 % increase in heart diseases mortality in the NHANES cohort; both MetS and CircS were significantly associated with increased risks of mortality from heart diseases (MetS: HR = 1.68; 95 % CI, 1.58–1.79; CircS: HR = 1.78; 95 % CI, 1.66–1.90), cancers (MetS: HR = 1.19; 95 % CI, 1.15–1.24; CircS: HR = 1.24; 95 % CI, 1.19–1.29), CVD (MetS: HR = 1.56; 95 % CI, 1.48–1.64; CircS: HR = 1.66; 95 % CI, 1.56–1.75), ischemic heart disease (MetS: HR = 1.81; 95 % CI, 1.68–1.96; CircS: HR = 1.93; 95 % CI, 1.79–2.09), stroke (MetS: HR = 1.36; 95 % CI, 1.21–1.53; CircS: HR = 1.42; 95 % CI, 1.24–1.61), and all-cause mortality (MetS: HR = 1.30; 95 % CI, 1.26–1.33; CircS: HR = 1.42; 95 % CI, 1.38–1.46) in the UKB cohort. CircS showed stronger associations with all mortality outcomes across both cohorts. Subgroup analyses revealed stronger associations in middle-aged adults, but weaker associations in those ≥ 70 years. CircS-based models consistently outperformed MetS-based models in terms of AIC and BIC.</div></div><div><h3>Conclusions</h3><div>CircS may provide a more comprehensive and interpretable framework for mortality risk prediction than MetS. Its potential incorporation into clinical and public health practice warrants further investigation.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112919"},"PeriodicalIF":7.4,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The miR-200 family in the context of obesity and type 2 diabetes","authors":"Carmen Lambert ,&nbsp;Elsa Villa-Fernández ,&nbsp;Ana Victoria García ,&nbsp;Miguel García-Villarino ,&nbsp;Judit Fernández ,&nbsp;Aldara Martin-Alonso ,&nbsp;Jessica Ares-Blanco ,&nbsp;Tomás González-Vidal ,&nbsp;Pedro Pujante ,&nbsp;Raquel Rodríguez-Uría ,&nbsp;Sandra Sanz-Navarro ,&nbsp;María Moreno-Gijón ,&nbsp;José Manuel Fernández-Real ,&nbsp;Mario F. Fraga ,&nbsp;Elías Delgado","doi":"10.1016/j.diabres.2025.112911","DOIUrl":"10.1016/j.diabres.2025.112911","url":null,"abstract":"<div><div>The miR-200 family is a highly conserved group of five microRNAs (miRNAs) extensively studied in cancer biology. However, its role in metabolic-related diseases remains poorly understood. This study aimed to evaluate the expression patterns of the miR-200 family in visceral white adipose tissue (vWAT) from individuals with different metabolic statuses.</div><div>Expression levels of miR-200 family members were analyzed in vWAT samples from 94 participants divided into three groups: normal weight without type 2 diabetes (noOB-noT2D;n = 19), individuals with obesity and without T2D (OB-noT2D;n = 45), and individuals with both obesity and T2D (OB-T2D;n = 30). PCA, correlation analysis, and functional enrichment<!--> <!-->were performed to explore the biological roles of the miR-200 family in metabolic dysfunction.</div><div>Significant differential expression was observed for hsa-miR-200b-3p (p = 0.010), hsa-miR-200c-3p (p = 0.002), and hsa-miR-141-3p (p = 0.004) across groups. Specifically, hsa-miR-200b-3p was upregulated only in the OB-noT2D group compared to noOB-noT2D, whereas hsa-miR-200c-3p and hsa-miR-141-3p were significantly upregulated in both groups of individuals with obesity relative to normal weight individuals. Additionally, positive correlations were found between BMI and the expression of hsa-miR-200c-3p, hsa-miR-141-3p, and hsa-miR-429. Distinct expression patterns emerged when miRNAs were grouped based on chromosomal location or functional classification. Functional enrichment analysis revealed pathways associated with insulin signaling, inflammation, and immune response.</div><div>These results highlight the potential of miR-200 family members as biomarkers and therapeutic targets in metabolic disease.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112911"},"PeriodicalIF":7.4,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triglyceride glucose-body mass index and the risk of gestational diabetes mellitus: a prospective pregnancy nutrition cohort study","authors":"Lihua Lin ,&nbsp;Libo Xu ,&nbsp;Jiayi Dong ,&nbsp;Libin Song ,&nbsp;Xiaoyan Ye ,&nbsp;Juan Lin ,&nbsp;Chong Miao","doi":"10.1016/j.diabres.2025.112901","DOIUrl":"10.1016/j.diabres.2025.112901","url":null,"abstract":"<div><h3>Background</h3><div>The 75 g oral glucose tolerance test (OGTT) fails to identify high-risk gestational diabetes mellitus (GDM) early in pregnancy. The triglyceride-glucose-body mass index (TyG-BMI), an insulin resistance marker, shows promise in predicting metabolic diseases, but hasn’t been studied for GDM before this study.</div></div><div><h3>Methods</h3><div>This prospective cohort study analyzed 1,704 pregnant women from the Fujian Pregnancy Nutrition Cohort (FPNC) in Southeast China. Associations between first-trimester TyG-BMI and GDM were assessed by linear regression, generalized linear models, mediation, and population attributable fraction (PAF) analyses.</div></div><div><h3>Results</h3><div>Higher TyG-BMI increased GDM risk dose-dependently (Q4 vs. Q1 RR: GDM = 2.48, IFG = 3.75, IGT = 1.84, IFSG = 13.00). Leukocytes mediated 13.15 % of the association. PAF indicated 28.44 % of GDM and 67.29 % of IFSG cases were attributable to elevated TyG-BMI.</div></div><div><h3>Conclusions</h3><div>The baseline TyG-BMI in early pregnancy is a robust predictor of GDM and its subtypes. It could be integrated into early pregnancy screening to identify high-risk women before OGTT, enabling earlier interventions. Anti-inflammatory management could be explored for high-risk women with elevated TyG-BMI.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112901"},"PeriodicalIF":7.4,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Tirzepatide on diet-related quality of life and treatment satisfaction in people with type 2 diabetes mellitus: a retrospective cross-sectional study","authors":"Shunsuke Kato ,&nbsp;Ayaka Kokita ,&nbsp;Hana Akanuma ,&nbsp;Shogo Iwamura ,&nbsp;Yuya Takahashi ,&nbsp;Ryota Kusumi ,&nbsp;Sakiko Abe ,&nbsp;Kana Sasaki ,&nbsp;Hitomi Otomo ,&nbsp;Sayaka Ando ,&nbsp;Mitsuhiko Nara ,&nbsp;Aiko Nara ,&nbsp;Takenobu Tadika ,&nbsp;Tatsunori Shimizu ,&nbsp;Takehiro Sato ,&nbsp;Tsukasa Morii ,&nbsp;Hiroki Fujita ,&nbsp;Daisuke Matsuda ,&nbsp;Hironori Waki","doi":"10.1016/j.diabres.2025.112913","DOIUrl":"10.1016/j.diabres.2025.112913","url":null,"abstract":"<div><h3>Aims</h3><div>To explore how Tirzepatide (TZP) treatment influences diet-related quality of life (QoL) and thus treatment satisfaction.</div></div><div><h3>Methods</h3><div>This retrospective observational study analyzed 95 people with type 2 diabetes mellitus treated with TZP. We evaluated measurements before and after TZP treatment for clinical parameters (including BMI and HbA1c) and, via validated questionnaires, patient-reported treatment satisfaction and diet-related QoL (including the Diabetes Diet-Related Quality of Life-Revised 9 (DDRQOL-R-9)). We used Spearman correlations and multiple regression analyses to identify predictors of treatment satisfaction.</div></div><div><h3>Results</h3><div>TZP treatment led to significant reduction of median HbA1c (7.4 % to 6.4 %) and body weight (77.2 kg to 70.6 kg). Median diet-related QoL, specifically the “perceived merits of dietary therapy”, increased from 58.3 [IQR 50.0, 75.0] to 67.7 [50.0, 83.3] (p &lt; 0.01). Multiple regression analysis identified changes in BMI (standardized β = − 0.21, p = 0.030) and changes in diet-related QoL “perceived merits of dietary therapy” (β = 0.23, p = 0.019) as independent predictors of DTSQs scores post-TZP treatment.</div></div><div><h3>Conclusion</h3><div>Despite TZP’s appetite-suppressing effects, diet-related QoL, particularly the “perceived merits of dietary therapy”, significantly increased with treatment, serving as an independent and substantial contributor to patient satisfaction, comparable to the impact of body weight reduction.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112913"},"PeriodicalIF":7.4,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial","authors":"Stacey M. Sklepinski ,&nbsp;Yihong Deng ,&nbsp;Kavya Sindu Swarna ,&nbsp;Jeph Herrin ,&nbsp;Eric C. Polley ,&nbsp;Joshua J. Neumiller ,&nbsp;Rodolfo J. Galindo ,&nbsp;Guillermo E. Umpierrez ,&nbsp;Joseph S. Ross ,&nbsp;Bijan J. Borah ,&nbsp;Bradley A. Maron ,&nbsp;Mindy M. Mickelson ,&nbsp;Rozalina G. McCoy","doi":"10.1016/j.diabres.2025.112910","DOIUrl":"10.1016/j.diabres.2025.112910","url":null,"abstract":"<div><h3>Aim</h3><div>To compare the cardiovascular outcomes of glucagon-like peptide-1 receptor agonists (GLP-1RAs) among adults with type 2 diabetes mellitus (T2D) at moderate cardiovascular risk.</div></div><div><h3>Methods</h3><div>We emulated a target trial using claims data of adults with T2D at moderate cardiovascular risk who initiated dulaglutide, exenatide, liraglutide, or semaglutide between 01/01/2014–12/31/2021. Random treatment assignment was emulated by propensity scores and incorporated into inverse probability of treatment weighted (IPTW) Cox models. Outcomes were time to composite major adverse cardiovascular events (MACE: myocardial infarction, stroke, and all-cause mortality), expanded MACE (MACE, hospitalization for heart failure, and revascularization) and its components, and severe hypoglycemia.</div></div><div><h3>Results</h3><div>After IPTW, 35,572 patients initiated dulaglutide, 4376 initiated exenatide, 8843 initiated liraglutide, and 33,063 initiated semaglutide. Compared to dulaglutide, semaglutide was associated with lower risk of MACE (HR 0.85, 95CI % 0.78–0.93), expanded MACE (HR 0.92, 95CI % 0.87–0.96), all-cause mortality (HR 0.81, 95CI % 0.71–0.92), stroke (HR 0.82, 95CI % 0.70–0.97), and revascularization (HR 0.93, 95CI % 0.88–0.99), while liraglutide was associated with lower risk of MACE (HR 0.84, 95CI % 0.72–0.97) and all-cause mortality (HR 0.79, 95CI % 0.64–0.99).</div></div><div><h3>Conclusions</h3><div>Among GLP-1RAs, semaglutide and liraglutide were associated with the greatest cardiovascular risk reduction in patients with T2D at moderate cardiovascular risk.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112910"},"PeriodicalIF":7.4,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of SGLT2 inhibitors and GLP-1 receptor agonists with the risk of Parkinson’s disease in patients with type 2 diabetes: A propensity score–matched cohort study with meta-analysis","authors":"Jia-Ai Yeh ,&nbsp;Shu-Man Lin ,&nbsp;Yu-Chang Liu ,&nbsp;Ji-Ze Hsu ,&nbsp;Amy Huaishiuan Huang ,&nbsp;Kashif M. Munir ,&nbsp;Carol Chiung-Hui Peng ,&nbsp;Ching-Hui Loh ,&nbsp;Huei-Kai Huang","doi":"10.1016/j.diabres.2025.112914","DOIUrl":"10.1016/j.diabres.2025.112914","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to investigate the association between sodium-glucose cotransporter 2 inhibitors (SGLT2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and the risk of Parkinson’s disease (PD) in patients with type 2 diabetes (T2D).</div></div><div><h3>Methods</h3><div>We conducted a real-world cohort study using the TriNetX U.S. Research Network. Adults aged ≥ 50 years with T2D initiating SGLT2is, GLP-1RAs, or dipeptidyl peptidase-4 inhibitors (DPP4is) between 2015 and 2022 were included. A landmark analysis using a new-user, active-comparator design with propensity score matching was applied. The primary outcome was incident PD. A meta-analysis incorporating additional real-world studies was also performed.</div></div><div><h3>Results</h3><div>In total, 93,872, 110,366, and 95,838 patients were included in the SGLT2i vs. DPP4i, GLP-1RA vs. DPP4i, and SGLT2i vs. GLP-1RA comparisons, respectively. SGLT2i users had a significantly lower risk of PD compared with both DPP4i users (HR = 0.80, 95 % CI: 0.69–0.93, p = 0.003) and GLP-1RA users (HR = 0.80, 95 % CI: 0.69–0.93, p = 0.003). No significant difference was observed between GLP-1RA and DPP4i users (HR = 0.97, 95 % CI: 0.85–1.10, p = 0.656). The meta-analysis further supported the reduced PD risk associated with SGLT2i use.</div></div><div><h3>Conclusions</h3><div>SGLT2i use was associated with a significantly lower risk of PD compared with both DPP4i and GLP-1RA use in patients with T2D.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112914"},"PeriodicalIF":7.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycemic status, early-onset and late-onset dementia, dementia-free lifespan, and brain structure: A population-based cohort study","authors":"Chenglong Li ,&nbsp;Daijun He ,&nbsp;Chao Yang ,&nbsp;Luxia Zhang ,&nbsp;Rodica Pop-Busui","doi":"10.1016/j.diabres.2025.112909","DOIUrl":"10.1016/j.diabres.2025.112909","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate associations of glycemic status with incident early-onset dementia (EOD) and late-onset dementia (LOD), dementia-free life expectancy, brain MRI structure measures, as well as the mediation pathway of depressive episode.</div></div><div><h3>Methods</h3><div>A population-based cohort study based on UK Biobank, enrolling a total of 286 743 (mean [SD] age, 51.5 [5.9] years) and 330 103 participants (mean [SD] age, 60.7 [5.0] years) for analyzing EOD and LOD, respectively. Incident EOD was defined as dementia diagnosis before age 65, and LOD defined as dementia after age 65.</div></div><div><h3>Results</h3><div>Diabetes participants with optimal glycemic control respectively had a 47 % lower EOD incidence and a 17 % lower LOD incidence, up to 3.2 years longer dementia-free lifespan at age 50, and better dementia-related brain structure measures, compared to counterparts with worse glycemic status. Incident depressive episode mediated 18.8 % (<em>P</em> = 0.014) and 7.8 % (<em>P</em> &lt; 0.001) of associations between glycemic status with EOD and LOD, respectively.</div></div><div><h3>Conclusions</h3><div>Better glycemic status was associated with reduced EOD and LOD risks, prolonged dementia-free lifespan, and brain MRI measures, partiality mediated by depressive episode. These findings support the potential significance of reaching ideal glycemic status to prevent dementia onset and prolong dementia-free longevity at the early pre-symptomatic stage in young diabetes.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"229 ","pages":"Article 112909"},"PeriodicalIF":7.4,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145102612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}